Limits...
Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.

Fan M, He X, Xu X - Mol Med Rep (2015)

Bottom Line: Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies.As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma.In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China.

ABSTRACT
Renal carcinoma is the most common type of kidney cancer in adults and is responsible for ~90‑95% of the cases of kidney cancer. Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies. In the present study, a series of experiments were designed and performed to investigate whether the expression of TET1 is clinically correlated with clinical outcomes in renal carcinoma, and to examine the associations between TET1 expression level and the proliferation and migration in renal carcinoma cells. As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma. Furthermore, statistical analysis revealed a clinical correlation between low expression levels of TET1 and the prognosis of patients with renal carcinoma. When TET1 was overexpressed in renal carcinoma cells, the viability and invasive abilities of the cells were decreased, and the rate of apoptosis was increased. In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

Show MeSH

Related in: MedlinePlus

Expression levels of TET1 in renal carcinoma tissues. (A) TET1 was detected in renal carcinoma tissues using immunohistochemical staining. The tumor tissue samples were obtained from patients with either low or high grade renal carcinoma. Normal renal tissues were used as a control. (B) mRNA expression levels of TET1 were measured in the renal carcinoma and control tissue samples samples using reverse transcription-quantitative polymerase chain reaction. The mRNA expression levels of actin were used as an internal control *P<0.05, compared with normal tissue and adjacent tissue. (C) Protein expression levels of TET1 were determined in the renal carcinoma and control tissue samples. Lane 1 was from normal renal tissue, Lane 2 was from low tumor grade renal carcinoma and Lane 3 was from high tumor grade renal carcinoma. The protein expression levels of actin were used as an internal control. TET1, ten-eleven translocation methylcytosine dioxygenase 1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581741&req=5

f1-mmr-12-04-4837: Expression levels of TET1 in renal carcinoma tissues. (A) TET1 was detected in renal carcinoma tissues using immunohistochemical staining. The tumor tissue samples were obtained from patients with either low or high grade renal carcinoma. Normal renal tissues were used as a control. (B) mRNA expression levels of TET1 were measured in the renal carcinoma and control tissue samples samples using reverse transcription-quantitative polymerase chain reaction. The mRNA expression levels of actin were used as an internal control *P<0.05, compared with normal tissue and adjacent tissue. (C) Protein expression levels of TET1 were determined in the renal carcinoma and control tissue samples. Lane 1 was from normal renal tissue, Lane 2 was from low tumor grade renal carcinoma and Lane 3 was from high tumor grade renal carcinoma. The protein expression levels of actin were used as an internal control. TET1, ten-eleven translocation methylcytosine dioxygenase 1.

Mentions: Renal carcinoma samples were collected from patients diagnosed with low tumor grade and from patients with high tumor grade, as defined by the Price grading system. The expression of TET1 was determined in the two different groups of renal carcinoma using immunohistochemistry. Immunoreactivity for TET1 in the high tumor grade tissue samples was lower, compared with that in the low tumor grade tissue samples. Notably, the two tumor groups exhibited low immunoreactivity for TET1, compared with the control tissues (Fig. 1A). In agreement with the immunohistochemical results, the mRNA expression levels of TET1 were significantly lower in the high tumor grade tissues, compared with the low tumor grade tissues (Fig. 1B; P<0.05). In addition, the results of the western blotting revealed that the protein expression levels of TET1 were lower in the high tumor grade tissues, compared with the low grade tissues (Fig. 1C), which was consistent with the results from the immunohistochemistry and RT-PCR analyses. These analyses demonstrated that the expression levels of TET1 were lower in the renal carcinoma samples than in the control samples, particularly in the group containing tissues from patients diagnosed with high tumor grades. This suggested that the expression levels of TET1 may be involved in renal carcinogenesis.


Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.

Fan M, He X, Xu X - Mol Med Rep (2015)

Expression levels of TET1 in renal carcinoma tissues. (A) TET1 was detected in renal carcinoma tissues using immunohistochemical staining. The tumor tissue samples were obtained from patients with either low or high grade renal carcinoma. Normal renal tissues were used as a control. (B) mRNA expression levels of TET1 were measured in the renal carcinoma and control tissue samples samples using reverse transcription-quantitative polymerase chain reaction. The mRNA expression levels of actin were used as an internal control *P<0.05, compared with normal tissue and adjacent tissue. (C) Protein expression levels of TET1 were determined in the renal carcinoma and control tissue samples. Lane 1 was from normal renal tissue, Lane 2 was from low tumor grade renal carcinoma and Lane 3 was from high tumor grade renal carcinoma. The protein expression levels of actin were used as an internal control. TET1, ten-eleven translocation methylcytosine dioxygenase 1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581741&req=5

f1-mmr-12-04-4837: Expression levels of TET1 in renal carcinoma tissues. (A) TET1 was detected in renal carcinoma tissues using immunohistochemical staining. The tumor tissue samples were obtained from patients with either low or high grade renal carcinoma. Normal renal tissues were used as a control. (B) mRNA expression levels of TET1 were measured in the renal carcinoma and control tissue samples samples using reverse transcription-quantitative polymerase chain reaction. The mRNA expression levels of actin were used as an internal control *P<0.05, compared with normal tissue and adjacent tissue. (C) Protein expression levels of TET1 were determined in the renal carcinoma and control tissue samples. Lane 1 was from normal renal tissue, Lane 2 was from low tumor grade renal carcinoma and Lane 3 was from high tumor grade renal carcinoma. The protein expression levels of actin were used as an internal control. TET1, ten-eleven translocation methylcytosine dioxygenase 1.
Mentions: Renal carcinoma samples were collected from patients diagnosed with low tumor grade and from patients with high tumor grade, as defined by the Price grading system. The expression of TET1 was determined in the two different groups of renal carcinoma using immunohistochemistry. Immunoreactivity for TET1 in the high tumor grade tissue samples was lower, compared with that in the low tumor grade tissue samples. Notably, the two tumor groups exhibited low immunoreactivity for TET1, compared with the control tissues (Fig. 1A). In agreement with the immunohistochemical results, the mRNA expression levels of TET1 were significantly lower in the high tumor grade tissues, compared with the low tumor grade tissues (Fig. 1B; P<0.05). In addition, the results of the western blotting revealed that the protein expression levels of TET1 were lower in the high tumor grade tissues, compared with the low grade tissues (Fig. 1C), which was consistent with the results from the immunohistochemistry and RT-PCR analyses. These analyses demonstrated that the expression levels of TET1 were lower in the renal carcinoma samples than in the control samples, particularly in the group containing tissues from patients diagnosed with high tumor grades. This suggested that the expression levels of TET1 may be involved in renal carcinogenesis.

Bottom Line: Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies.As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma.In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China.

ABSTRACT
Renal carcinoma is the most common type of kidney cancer in adults and is responsible for ~90‑95% of the cases of kidney cancer. Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies. In the present study, a series of experiments were designed and performed to investigate whether the expression of TET1 is clinically correlated with clinical outcomes in renal carcinoma, and to examine the associations between TET1 expression level and the proliferation and migration in renal carcinoma cells. As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma. Furthermore, statistical analysis revealed a clinical correlation between low expression levels of TET1 and the prognosis of patients with renal carcinoma. When TET1 was overexpressed in renal carcinoma cells, the viability and invasive abilities of the cells were decreased, and the rate of apoptosis was increased. In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

Show MeSH
Related in: MedlinePlus